Nuvectis Pharma, Inc. (NVCT)
| Previous close | 11.78 |
| Open | 11.55 |
| Bid | 11.11 x 800 |
| Ask | 11.84 x 800 |
| Day's range | 11.13 - 11.79 |
| 52-week range | 6.21 - 18.65 |
| Volume | |
| Avg. volume | 43,668 |
| Market cap | 191.957M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.44 |
| Earnings date | 03 Nov 2023 - 09 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 20.67 |
GlobeNewswireNuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows: Date Tuesday, September
- GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming scientific presentations for NXP800 at the 2023 AACR Special Conference In Cancer Research: Ovarian Cancer (October 5-7, 2023, Boston, MA) and for NXP800 and NXP900 at the 2023 AA
Simply Wall St.With 67% ownership, insiders at Nuvectis Pharma, Inc. (NASDAQ:NVCT) are pretty optimistic and have been buying recently
Key Insights Significant insider control over Nuvectis Pharma implies vested interests in company growth The top 4...
